Formulary Drug Review: Odevixibat. 2023

Terri L Levien, and Danial E Baker
Washington State University, Spokane, WA, USA.

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

UI MeSH Term Description Entries

Related Publications

Terri L Levien, and Danial E Baker
February 2018, Hospital pharmacy,
Terri L Levien, and Danial E Baker
December 2017, Hospital pharmacy,
Terri L Levien, and Danial E Baker
October 2017, Hospital pharmacy,
Terri L Levien, and Danial E Baker
September 2017, Hospital pharmacy,
Terri L Levien, and Danial E Baker
November 2017, Hospital pharmacy,
Terri L Levien, and Danial E Baker
July 2017, Hospital pharmacy,
Terri L Levien, and Danial E Baker
June 2024, Hospital pharmacy,
Terri L Levien, and Danial E Baker
August 2019, Hospital pharmacy,
Terri L Levien, and Danial E Baker
January 1993, Journal of health care benefits,
Terri L Levien, and Danial E Baker
February 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Copied contents to your clipboard!